)
Visual
test
Jubilant Pharmova
Jubilant Pharmova (530019) investor relations material
Jubilant Pharmova Q3 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 25/26 earnings summary6 Feb, 2026
Executive summary
Q3'FY26 revenue grew 17% year-over-year to ₹21,161 million, driven by strong performance across all business segments, especially CDMO Sterile Injectables and CRDMO.
EBITDA increased 5% YoY, with margin at 14.5% for the quarter; normalized PAT declined due to higher depreciation.
Net profit for the quarter was ₹558 million, compared to ₹1,199 million in the previous quarter and ₹1,007 million in the same quarter last year.
Vision 2030 targets doubling revenue by FY30, EBITDA margin of 23–25%, zero net debt, and high teens ROCE.
The company completed the sale and transfer of its API business to a wholly-owned subsidiary, now classified as discontinued operations.
Financial highlights
Q3'FY26 revenue: Rs. 2,123 Cr (+17% YoY) / ₹21,161 million; 9M'FY26 revenue: Rs. 5,990 Cr (+13% YoY).
Q3'FY26 EBITDA: Rs. 310 Cr (+5% YoY); margin at 14.5%.
Normalized PAT for Q3'FY26: Rs. 86 Cr (-17% YoY); 9M'FY26: Rs. 313 Cr (+13% YoY).
Net profit for the quarter was ₹558 million; EPS at ₹3.52 (basic and diluted).
Q3'FY26 exceptional expense: Rs. 39 Cr due to labor code changes and temporary plant suspension; total exceptional expenses ₹397 million, including Canadian remediation and debt costs.
Outlook and guidance
Revenue expected to normalize from Q2'FY27 after temporary supply shortages in SPECT products.
PET radiopharmacy expansion and new product launches to drive future growth.
CDMO Sterile Injectables to double capacity at Spokane, with commercial batch production from FY27.
Proprietary novel drugs to explore monetization post clinical data readouts in CY2026.
The company continues to monitor regulatory changes, including new Labour Codes and proposed tax regime changes.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebJ
Strong growth, digital innovation, and margin expansion drive robust multi-year financial outlook. - 6 Feb004020
Operating profit rose on cost savings and high-value sales, with major US expansion underway. - 6 FebJOUT
Net sales up 31%, gross margin at 36.6%, and net loss narrowed to $3.3 million. - 6 FebPECO
Record 2025 occupancy and 7% Core FFO growth; 2026 targets 5.5% FFO growth and strong acquisitions. - 6 FebPROV
Q2 FY2026 net income rose 65% year-over-year, with higher margins and strong credit quality. - 6 FebNVDA
AI-driven digital twins and accelerated computing are set to revolutionize industrial design and manufacturing. - 6 FebCDP
2025 FFO/share rose 5.8% to $2.72, with strong leasing and investment; 2026 guidance signals more growth. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
- 6 FebCRINet loss deepened on lower sales and higher costs, but major new contracts and restructuring are underway.
Next Jubilant Pharmova earnings date
Q4 202622 May, 2026
Jubilant Pharmova
Next Jubilant Pharmova earnings date
Q4 202622 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Jubilant Pharmova Limited is a pharmaceutical company engaged in the development, manufacturing, and supply of specialty pharmaceuticals and contract research services. The company operates across segments including contract development and manufacturing (CDMO), radiopharma, allergy therapy products, and proprietary pharmaceuticals. It also provides drug discovery and development services to global pharmaceutical and biotechnology companies. The company is headquartered in Noida, India, and its shares are listed on the BSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage